Dr Reddys Laboratories (RDY) Capital Expenditures (2009)
Dr Reddys Laboratories (RDY) posted quarterly Capital Expenditures of -$119.0 million for Q4 2009, up 24.2% quarter-over-quarter from -$157.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Capital Expenditures (2009) Analysis & Trends
Dr Reddys Laboratories' Capital Expenditures history runs 1 years deep, the most recent figure standing at -$119.0 million for Q4 2009.
- In Q4 2009, Capital Expenditures changed N/A year-over-year to -$119.0 million; the TTM figure through Dec 2009 stood at -$371.8 million (changed N/A YoY), while the FY2026 annual figure was $249.0 million, down 22.67% from the prior year.
- Capital Expenditures for Q4 2009 stood at -$119.0 million, up from -$157.0 million in the prior quarter.
- The five-year high for Capital Expenditures was -$104.0 million in Q2 2009, with the low at -$157.0 million in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 8.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -119.00 Mn |
| Dec 31, 2009 | -119.00 Mn |
| Sep 30, 2009 | -157.00 Mn |
| Sep 30, 2009 | -157.00 Mn |
| Jun 30, 2009 | -104.00 Mn |
| Jun 30, 2009 | -104.00 Mn |